Clinical Trial Update: A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastric and Colorectal Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy [Phase 2]

View source ↗

Summary

Phase II single-arm exploratory study of pemigatinib in advanced gastric and colorectal cancer patients with FGFR alterations after standard therapy failure.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Gastric Cancer

Drugs mentioned

• Pemigatinib (pemigatinib)

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Gastric and Colorectal Cancer | Phase 2 | Status: UNKNOWN